Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (191-200 of 596) with videos related to

Pageof 60
Sort By:
The Hematology Journal : the Official Journal of the European Haematology Association|October 23, 2002
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemiaClaudia Schoch, Susanne Schnittger, Wolfgang Kern, et al.
Oncogene|June 9, 2021
How artificial intelligence might disrupt diagnostics in hematology in the near futureWencke Walter, Claudia Haferlach, Niroshan Nadarajah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Haematologica|April 10, 2025
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case reportJana Wobst, Marietta Truger, Constance Baer, et al.
Hemasphere|November 15, 2019
Molecular characterization of AML with <i>RUNX1-RUNX1T1</i> at diagnosis and relapse reveals net loss of co-mutationsAlexander Höllein, Niroshan Nadarajah, Manja Meggendorfer, et al.
Leukemia & Lymphoma|January 28, 2026
Clonal independence of CHIP-associated mutations in multiple myelomaJana Wobst, Natalie Wossidlo, Marietta Truger, et al.
British Journal of Haematology|September 24, 2016
Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemiaSimone Weber, Torsten Haferlach, Tamara Alpermann, et al.
Genes, Chromosomes & Cancer|March 8, 2005
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypesTorsten Haferlach, Alexander Kohlmann, Susanne Schnittger, et al.
Genes, Chromosomes & Cancer|December 14, 2011
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic eventsClaudia Haferlach, Ulrike Bacher, Susanne Schnittger, et al.
Haematologica|September 21, 2014
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemiaManja Meggendorfer, Torsten Haferlach, Tamara Alpermann, et al.
Pageof 60

Showing results (191-200 of 596) with videos related to

Sort By:
Pageof 60
The Hematology Journal : the Official Journal of the European Haematology Association|October 23, 2002
Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemiaClaudia Schoch, Susanne Schnittger, Wolfgang Kern, et al.
Oncogene|June 9, 2021
How artificial intelligence might disrupt diagnostics in hematology in the near futureWencke Walter, Claudia Haferlach, Niroshan Nadarajah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study GroupGeorg Lenz, Martin Dreyling, Eva Schiegnitz, et al.
Haematologica|April 10, 2025
Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post cytotoxic therapy: a case reportJana Wobst, Marietta Truger, Constance Baer, et al.
Hemasphere|November 15, 2019
Molecular characterization of AML with <i>RUNX1-RUNX1T1</i> at diagnosis and relapse reveals net loss of co-mutationsAlexander Höllein, Niroshan Nadarajah, Manja Meggendorfer, et al.
Leukemia & Lymphoma|January 28, 2026
Clonal independence of CHIP-associated mutations in multiple myelomaJana Wobst, Natalie Wossidlo, Marietta Truger, et al.
British Journal of Haematology|September 24, 2016
Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemiaSimone Weber, Torsten Haferlach, Tamara Alpermann, et al.
Genes, Chromosomes & Cancer|March 8, 2005
AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypesTorsten Haferlach, Alexander Kohlmann, Susanne Schnittger, et al.
Genes, Chromosomes & Cancer|December 14, 2011
ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic eventsClaudia Haferlach, Ulrike Bacher, Susanne Schnittger, et al.
Haematologica|September 21, 2014
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemiaManja Meggendorfer, Torsten Haferlach, Tamara Alpermann, et al.
Pageof 60